Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

Illuminating Cancer Resistance in Elephants

DOI: 10.1158/2159-8290.CD-NB2015-147 Published December 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Elephants are perhaps best known for their remarkably good memory and long life span—60 years on average. They also have an unusually generous share of the tumor suppressor gene TP53 and seldom develop cancer, which may contribute to their longevity (JAMA 2015;314:1850–60).

Joshua Schiffman, MD, a pediatric oncologist at the University of Utah's Huntsman Cancer Institute in Salt Lake City and one of the study's senior authors, first learned 3 years ago that co–senior author Carlo Maley, PhD, an evolutionary biologist at Arizona State University in Tempe, had found at least 20 copies of TP53 in both African and Asian elephants. Whole-genome sequencing revealed that one was an ancestral copy comparable to TP53 in other mammals, including the much smaller hyrax, the elephant's closest living relative. The rest were retrogenes, or modified duplicates, that emerged after the evolutionary split between hyrax and elephant. This fascinated Schiffman, because “it suggested a natural protection, evolved over millions of years, against diseases like cancer.”

Schiffman and Maley analyzed 36 mammalian species, from striped grass mice to elephants, and showed that the probability of carcinogenesis did not increase with body size and life span. Combing through 644 deaths in the Elephant Encyclopedia database, the researchers estimated the elephant cancer mortality rate to be 4.81%. In contrast, human cancer mortality rates range from 11% to 25%.

The team then assessed DNA damage repair in elephant cells, healthy human cells, and cells from patients with Li-Fraumeni syndrome (LFS)—who have a compromised copy of TP53 with one functional allele instead of two, making them highly cancer-prone—by bombarding the cells with ionizing radiation and doxorubicin, which induce DNA double-strand breaks.

“We expected that DNA damage repair in elephant cells would be more efficient than human cells, and quite off the charts compared to LFS cells,” Schiffman says, “so we were disappointed to find that double-strand breaks weren't repaired any faster in elephant versus human cells.” Instead, the researchers found that elephant cells had higher rates of apoptosis: twice that of healthy human cells, and five times that of LFS cells. “Thinking about it, this made sense,” Schiffman says. “Eliminating damaged cells could be an effective way to protect from cancer, instead of taking a chance that the DNA damage will be incompletely repaired and escape into future populations.”

Figure1

Joshua Schiffman led a study that could explain why elephants rarely get cancer.

An editorial accompanying this study allowed the plausibility of elephants owing “their relatively cancer-free longevity to the acquisition… of extra copies of TP53” (JAMA 2015;314:1806–7). The authors added, though, that “it is perhaps unlikely that the p53 gene deserves all the credit,” noting that other animals—for instance, bowhead whales and naked mole rats—have evolved different ways to resist cancer. They also pointed out that most human cancers are linked to lifestyles “not found among animals.”

“Our cancer risk is artificially higher because of smoking, drinking, and other bad habits,” Schiffman agrees. “However, there are inherent biological differences between human and elephant cells that can't be explained by lifestyle or environmental factors.”

The researchers aren't directly connecting an elephant's low likelihood of cancer to its additional copies of TP53, Schiffman stresses—“we think there's a relationship here, but we have to further explore this mechanism.” They're now closely analyzing individual TP53 retrogenes, each being distinctly different; and exploring the potential involvement of other molecular pathways in elephants' robust apoptotic response to DNA damage.

“In comparative oncology, we've learned a lot about human cancer from cancer-prone animals,” Schiffman observes. “By shifting the focus to understanding why some animals are naturally cancer-resistant, we could learn still more.”

Notes

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Illuminating Cancer Resistance in Elephants
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Illuminating Cancer Resistance in Elephants
Cancer Discov December 1 2015 (5) (12) 1229; DOI: 10.1158/2159-8290.CD-NB2015-147

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Illuminating Cancer Resistance in Elephants
Cancer Discov December 1 2015 (5) (12) 1229; DOI: 10.1158/2159-8290.CD-NB2015-147
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
  • The National Cancer Act at 50
  • Congress Approves Increase in Cancer Funding
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement